This site is intended for
U.S.
Healthcare Professionals only.
I-O Biomarkers
Click a research area to learn more.
Immuno-Oncology
(I-O) biomarkers may be used to advance precision medicine
Bristol Myers Squibb is committed to investigating four key areas of I-O biomarker research.
Click on one of the biomarker categories to learn more.
Tumor Antigens
Tumor antigens are recognized as nonself or foreign by the host immune system.1 They can initiate the adaptive immune response by priming the immune system.1,2 Several Immuno-Oncology
Learn about:
MSI-H/dMMRInflamed Tumor Markers
Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment.3,4 Several Immuno-Oncology
Learn about:
Inflammation GeneSignature
Immune Suppression Markers
Cells and proteins within the tumor and its microenvironment can suppress T-cell activation, promote T-cell exhaustion, or activate regulatory T-cells.5,6 Several exploratory
Immuno-Oncology
Learn about:
Immuno-Oncology (I-O) biomarkers may be used to advance precision medicine
Bristol Myers Squibb is committed to investigating four key areas of I-O biomarker research. Tap on one of the biomarker categories to learn more.
Tumor antigens are recognized as nonself or foreign by the host immune system.1 They can initiate the adaptive immune response by priming the immune system.1,2 Several
Immuno-Oncology (I-O) biomarkers related to tumor antigens are currently under investigation.
Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment.3,4 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.
Cells and proteins within the tumor and its microenvironment can suppress
Many factors in the host envrionment may play a role in modulating an immune response. Outside of the tumor microenvironment, factors such as smoking, diet, UV exposure, infectious agents, and the gut microbiome can favorably or unfavorably affect the antitumor response.7-9
Tap the links below to navigate to the individual biomarker pages.
I-O biomarkers: Under investigation for their role in immuno-therapy
Learn more about where our I-O biomarker research is focused
Get I-O Resources
Order or download
educational tools for your
patients and practice
REFERENCES–I-O Biomarkers
1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. 2. Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456-465. 3. Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume 1 – pre-analytical and analytical validation. J Immunother Cancer.2016;4:76. 4. Hedge PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res.